title: Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
authors.affiliation: Department of Clinical Pharmacology, Medizinische Hochschule Hannover, Hannover, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Jordan
authors.affiliation: Department of Pharmacology, Technische Universität Dresden, Dresden, Germany.
authors.forename: Ali
authors.initials: A
authors.lastname: El-Armouche
authors.affiliation: Clinical Study Centre Professor Hanefeld, GWT TU-Dresden GmbH, Dresden, Germany.
authors.forename: Markolf
authors.initials: M
authors.lastname: Hanefeld
authors.affiliation: Medical Clinic III, Universitätsklinikum "Carl Gustav Carus," Paul Langerhans Institute Dresden, Technische Universität Dresden, Dresden, Germany.|German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.|Division of Diabetes and Nutritional Sciences, Rayne Institute, King's College London, London, U.K.
authors.forename: Stefan R
authors.initials: SR
authors.lastname: Bornstein
authors.affiliation: Clinical Study Centre Professor Hanefeld, GWT TU-Dresden GmbH, Dresden, Germany andreas.birkenfeld@uniklinik-dresden.de.|Medical Clinic III, Universitätsklinikum "Carl Gustav Carus," Paul Langerhans Institute Dresden, Technische Universität Dresden, Dresden, Germany.|German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.|Division of Diabetes and Nutritional Sciences, Rayne Institute, King's College London, London, U.K.
authors.forename: Andreas L
authors.initials: AL
authors.lastname: Birkenfeld
mesh_terms: D006801:Humans; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2
chemical_list: D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2